Lakefront Biotherapeutics (GLPGF) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Net Income towards Common Stockholders Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | 19.87% |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | -129.59% |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | 6.30% |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 10.23% |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 91.31% |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | 17.25% |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 37.44% |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | -45.23% |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -333.24% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -333.24% |
| Mar 31, 2026 | -12.01% |
| Dec 31, 2025 | 1,070.24% |
| Sep 30, 2025 | -206.57% |
| Jun 30, 2025 | 120.19% |
| Mar 31, 2025 | -121.05% |
| Dec 31, 2024 | 980.11% |
| Sep 30, 2024 | 16.28% |
| Jun 30, 2024 | 39.92% |
| Mar 31, 2024 | 102.90% |
| Dec 31, 2023 | 921.20% |
| Sep 30, 2023 | 42.95% |
| Jun 30, 2023 | 26.10% |
| Mar 31, 2023 | 34.74% |
| Dec 31, 2022 | 56.40% |
| Sep 30, 2022 | -62.19% |
| Jun 30, 2022 | 27.41% |
| Mar 31, 2022 | 35.36% |
| Dec 31, 2021 | -78.46% |
| Sep 30, 2021 | -132.12% |